AB SCIEX and Dalton Pharma Services entered a research collaboration to develop antibody-drug conjugate (ADC) analysis capabilities. The companies said this will include development of a more definitive and comprehensive method for the identification of drug loading and position of conjugation on macromolecules.
AB SCIEX will utilize Dalton’s specialized synthetic conjugation capabilities. The research will focus on the preparation and characterization of ADC’s by Dalton scientists working with AB SCIEX experts to develop standardized analytical procedures on the TripleTOF® 5600+ system with SelexION™ technology and the new TripleTOF® 6600 platform for determining the chemical structures of conjugated molecules.
"A key challenge for developing successful ADC medicines is understanding the structure and payload of the final molecule,” explained Tan Quach, chemistry manager at Dalton Pharma Services. “Determining where the drug attaches to a particular antibody early in its development and the number of drug molecules on the antibody are important indicators of the likely success of a new ADC."
"Recent advances in mass spectrometry have provided a solution to answer the challenging questions in terms of understanding ADC drug development and working within a biological matrix,” added Chris Radloff, vice president, LC/ MS business at AB SCIEX. “Utilizing these molecules is difficult and by forming this partnership, ADC developers can now reduce complications, and obtain accurate results that will ultimately lead to safer, more effective therapies.”
The partnership will continue to co-develop standardized analytical procedures utilizing mass spectrometry technology and publish technical papers in upcoming months.